Detalles de la búsqueda
1.
Emtricitabine and tenofovir alafenamide vs emtricitabine and tenofovir disoproxil fumarate for HIV pre-exposure prophylaxis (DISCOVER): primary results from a randomised, double-blind, multicentre, active-controlled, phase 3, non-inferiority trial.
Lancet
; 396(10246): 239-254, 2020 07 25.
Artículo
en Inglés
| MEDLINE | ID: mdl-32711800
2.
Twelve-month effectiveness and safety of bictegravir/emtricitabine/tenofovir alafenamide in people with HIV from the Canadian cohort of the observational BICSTaR study.
Medicine (Baltimore)
; 103(16): e37785, 2024 Apr 19.
Artículo
en Inglés
| MEDLINE | ID: mdl-38640301
3.
Recognizing cognitive and psychiatric changes in the post-highly active antiretroviral therapy era.
Can J Infect Dis Med Microbiol
; 23(4): 209-15, 2012.
Artículo
en Inglés
| MEDLINE | ID: mdl-24294277
4.
Randomized controlled trial of once-daily tenofovir, lamivudine, and lopinavir/ritonavir versus remaining on the same regimen in virologically suppressed HIV-infected patients on their first PI-containing HAART regimen.
HIV Clin Trials
; 8(5): 259-68, 2007.
Artículo
en Inglés
| MEDLINE | ID: mdl-17956827
5.
Plasma HIV-1 RNA decline within the first two weeks of treatment is comparable for nevirapine, efavirenz, or both drugs combined and is not predictive of long-term virologic efficacy: A 2NN substudy.
J Acquir Immune Defic Syndr
; 38(3): 296-300, 2005 Mar 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-15735447
Resultados
1 -
5
de 5
1
Próxima >
>>